GO:0043066 negative regulation of apoptotic process: Pro-Survival Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043066 (negative regulation of apoptotic process) describes any cellular process that stops, prevents, or reduces the frequency, rate or extent of apoptotic cell death.
• It is a biological_process term that includes anti-apoptotic signaling, inhibition of caspase activation, and ubiquitin-dependent degradation of pro-apoptotic factors.
• Key molecular players include SIRT1, IAP family proteins, BCL-2 family members, and ubiquitin-proteasome system components.
• Dysregulation of this process contributes to cancer, autoimmune disease, and therapy resistance in hematological malignancies.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of anti-apoptotic genes.
• EDITGENE provides end-to-end CRISPR cell model services and library screening to study negative regulation of apoptosis at scale.
Description
Negative regulation of apoptotic process (GO:0043066) is a fundamental biological process that counteracts programmed cell death, allowing cells to survive under stress or during development. Apoptosis is a genetically controlled form of cell death essential for tissue homeostasis, and its negative regulation ensures that cells do not die inappropriately. This GO term encompasses all molecular events that inhibit or reduce the frequency, rate, or extent of apoptosis, including anti-apoptotic signaling, inhibition of caspase activation, and degradation of pro-apoptotic proteins. Understanding this process is critical because its dysregulation is a hallmark of many diseases, including cancer, where tumor cells evade apoptosis, and autoimmune disorders, where cells fail to die. Moreover, therapeutic resistance in hematological malignancies often involves upregulation of anti-apoptotic mechanisms. Researchers study this process using gene editing, functional genomics, and biochemical assays to identify new targets for intervention. The QuickGO definition provides a precise scope: any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
negative regulation of apoptotic process At A Glance
| GO ID | GO:0043066 |
|---|---|
| GO term | negative regulation of apoptotic process |
| Ontology | biological_process |
| Synonym | anti-apoptosis; apoptosis inhibitor activity; down regulation of apoptosis; down-regulation of apoptosis; downregulation of apoptosis; inhibition of apoptosis; negative regulation of apoptosis; pro-survival |
| Major function | Stops, prevents, or reduces the frequency, rate or extent of apoptotic cell death |
| Related processes | Apoptotic process (GO:0006915), positive regulation of apoptotic process (GO:0043065), regulation of apoptotic process (GO:0042981) |
| Key regulators | SIRT1, IAP family, BCL-2 family, ubiquitin-proteasome system, autophagy proteins |
| Disease relevance | Cancer, autoimmune diseases, neurodegeneration, ischemia-reperfusion injury |
What Is GO:0043066?
In simple terms, negative regulation of apoptotic process refers to all the cellular strategies that keep a cell alive by blocking or dampening the apoptotic death program. According to QuickGO, it is any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. This includes anti-apoptotic signaling pathways, inhibition of pro-apoptotic proteins, and upregulation of survival factors.
Why Is negative regulation of apoptotic process Important in Cell Biology?
Negative regulation of apoptotic process is essential for normal development, tissue homeostasis, and immune function, but its dysregulation underpins major human diseases. Cancer cells frequently hijack anti-apoptotic mechanisms to survive chemotherapy and radiation. In autoimmune diseases, defective apoptosis leads to accumulation of autoreactive immune cells. Conversely, excessive apoptosis contributes to neurodegeneration and ischemic injury. Understanding the molecular players and their regulation is therefore critical for developing targeted therapies.
• Cancer: Overexpression of anti-apoptotic proteins like BCL-2 and IAPs confers resistance to therapy.
• Autoimmunity: Impaired apoptosis of lymphocytes contributes to autoimmune pathology.
• Neurodegeneration: Inappropriate survival or death of neurons is linked to aging and neurodegenerative diseases.
• Ischemia-reperfusion injury: SIRT1 and Ikaros signaling modulate apoptosis and pyroptosis in liver and kidney.
• Infectious disease: SIRT1 activation negatively regulates apoptosis in Mycobacterium tuberculosis-infected macrophages.
• Hematological malignancies: Cytotoxic agents can both induce and inhibit apoptotic pathways, affecting treatment response.
• Aging: Age-related changes in apoptosis regulation impact tissue degeneration and cancer risk.
• Drug discovery: Anti-apoptotic proteins are major targets for small-molecule inhibitors (e.g., BH3 mimetics).
• CRISPR screening: Genome-wide knockout screens identify novel negative regulators of apoptosis.
• Therapeutic resistance: Ubiquitin-proteasome system components that degrade pro-apoptotic factors are emerging targets.
What Happens During negative regulation of apoptotic process?
Inhibition of Caspase Activation
In simple terms: The cell blocks the executioner enzymes that carry out apoptosis.
Caspases are cysteine proteases that execute apoptosis. Negative regulation of apoptosis often involves inhibitors of apoptosis proteins (IAPs) that bind and inhibit caspases, preventing their activation. IAPs can also ubiquitylate caspases, targeting them for proteasomal degradation. This step is critical for preventing accidental cell death and is frequently dysregulated in cancer.
Ubiquitin-Proteasome-Mediated Degradation of Pro-Apoptotic Factors
In simple terms: The cell tags pro-death proteins for destruction by the proteasome.
The ubiquitin-proteasome system (UPS) plays a central role in negative regulation of apoptosis by degrading pro-apoptotic proteins such as BAX, BAK, and p53. E3 ubiquitin ligases recognize specific substrates and attach ubiquitin chains, leading to proteasomal degradation. This mechanism is exploited by cancer cells to lower pro-apoptotic protein levels and evade apoptosis.
Anti-Apoptotic BCL-2 Family Proteins
In simple terms: Survival proteins protect mitochondria from permeabilization.
BCL-2 family proteins include anti-apoptotic members (BCL-2, BCL-XL, MCL-1) that bind and sequester pro-apoptotic effectors (BAX, BAK) and BH3-only proteins, preventing mitochondrial outer membrane permeabilization and cytochrome c release. Overexpression of these proteins is a common mechanism of apoptosis resistance in hematological malignancies.
SIRT1 and Metabolic Regulation
In simple terms: SIRT1 is a survival factor that helps cells resist stress-induced death.
SIRT1, an NAD+-dependent deacetylase, negatively regulates apoptosis by deacetylating and modulating the activity of key apoptotic regulators such as p53, FOXO, and BAX. In Mycobacterium tuberculosis-infected macrophages, SIRT1 activation reduces apoptosis through BAX downregulation. In hepatic ischemia, myeloid Ikaros-SIRT1 signaling regulates inflammation and pyroptosis. SIRT1 is also negatively regulated by IRF9 in hyperlipidemia acute pancreatitis-associated kidney injury.
Autophagy and Cross-Talk with Apoptosis
In simple terms: Autophagy proteins can block apoptosis to promote survival.
The autophagy protein RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis, demonstrating cross-talk between autophagy and cell death pathways. This negative regulation is important for limiting inflammation and tissue damage. Thus, autophagy can serve as a pro-survival mechanism that inhibits apoptosis under certain conditions.
Key Genes Involved in GO:0043066 negative regulation of apoptotic process
The following genes and proteins are central to negative regulation of apoptotic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SIRT1 | Deacetylates p53, FOXO, BAX; promotes survival | Target in inflammation, ischemia, infection |
| BCL2 | Anti-apoptotic BCL-2 family protein; inhibits BAX/BAK | Overexpressed in lymphomas and leukemias |
| BCL2L1 (BCL-XL) | Anti-apoptotic; blocks mitochondrial permeabilization | Therapeutic target in cancer |
| MCL1 | Anti-apoptotic; sequesters BH3-only proteins | Resistance to BH3 mimetics |
| XIAP (BIRC4) | Inhibits caspases 3, 7, 9; E3 ligase | Cancer therapy target |
| BIRC2 (cIAP1) | Ubiquitylates caspases and RIPK1 | Regulates apoptosis and necroptosis |
| BIRC3 (cIAP2) | E3 ligase; inhibits apoptosis | NF-kB and apoptosis cross-talk |
| BAX | Pro-apoptotic; target of negative regulation | Knockout models for apoptosis studies |
| RIPK1 | Kinase; regulated by RUBCNL/PACER | Necroptosis and apoptosis balance |
| RUBCNL (PACER) | Autophagy protein; represses RIPK1-dependent apoptosis | Cross-talk autophagy-apoptosis |
| IRF9 | Negatively regulates SIRT1 | Hyperlipidemia acute pancreatitis |
| IKZF1 (Ikaros) | Transcription factor; regulates SIRT1 signaling | Liver ischemia and pyroptosis |
| TP53 | Pro-apoptotic; deacetylated by SIRT1 | Cancer and aging |
| FOXO3 | Transcription factor; deacetylated by SIRT1 | Stress resistance and longevity |
| CASP3 | Executioner caspase; inhibited by IAPs | Apoptosis assays |
| CASP9 | Initiator caspase; inhibited by XIAP | Intrinsic apoptosis pathway |
| BID | BH3-only protein; links extrinsic and intrinsic pathways | Apoptosis regulation |
How Is negative regulation of apoptotic process Regulated?
Negative regulation of apoptotic process is tightly controlled at multiple levels. SIRT1 activity is modulated by NAD+ availability and by interacting proteins such as IRF9, which negatively regulates SIRT1 in kidney injury. Ikaros (IKZF1) regulates SIRT1 signaling in hepatic inflammation. The ubiquitin-proteasome system controls the stability of pro-apoptotic proteins, with E3 ligases serving as key regulators. IAPs are themselves regulated by antagonists such as SMAC/DIABLO and by ubiquitination. Autophagy proteins like RUBCNL/PACER can repress RIPK1-dependent apoptosis, linking metabolic stress to cell death control. Additionally, cytotoxic agents can modulate both positive and negative regulation of apoptotic pathways in hematological malignancies.
negative regulation of apoptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCL2 | Lymphoma, leukemia; apoptosis resistance | Knockout and overexpression in cancer cell lines |
| SIRT1 | Inflammation, ischemia-reperfusion injury, infection | Knockout and knock-in mouse models |
| XIAP | Cancer; apoptosis inhibition | Point mutation and knockout in cancer cells |
| RUBCNL | Autophagy-apoptosis cross-talk; inflammation | Knockout and tagged knock-in |
| IRF9 | Hyperlipidemia acute pancreatitis; kidney injury | Knockout and overexpression models |
Cancer and Therapy Resistance
Cancer cells often evade apoptosis by upregulating anti-apoptotic proteins such as BCL-2, BCL-XL, MCL-1, and IAPs. This negative regulation of apoptosis contributes to resistance to chemotherapy and radiation. Targeting these proteins with BH3 mimetics or IAP antagonists is a major therapeutic strategy. Understanding the mechanisms of apoptosis inhibition is therefore critical for developing new cancer treatments.
Inflammatory and Ischemic Diseases
SIRT1-mediated negative regulation of apoptosis protects against inflammation and ischemia-reperfusion injury in the liver and kidney. In Mycobacterium tuberculosis-infected macrophages, SIRT1 activation reduces apoptosis through BAX downregulation. In hepatic ischemia, myeloid Ikaros-SIRT1 signaling regulates inflammation and pyroptosis. IRF9 negatively regulates SIRT1 in hyperlipidemia acute pancreatitis-associated kidney injury. These findings highlight the importance of apoptosis regulation in inflammatory diseases.
Aging and Neurodegeneration
Aging is associated with changes in the regulation of apoptosis, affecting tissue homeostasis and disease susceptibility. Dysregulated apoptosis contributes to neurodegeneration, where excessive cell death occurs, and to cancer, where cells fail to die. Understanding how negative regulation of apoptosis changes with age may reveal therapeutic targets for age-related diseases.
From negative regulation of apoptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X inhibit apoptosis? | CRISPR knockout followed by apoptosis induction |
| Does a point mutation in gene X affect anti-apoptotic function? | CRISPR point mutation knock-in |
| Does overexpression of gene X protect against apoptosis? | CRISPR overexpression (safe harbor knock-in) |
| Where is protein X localized during apoptosis inhibition? | Tagged knock-in (e.g., GFP) |
| What are the downstream targets of gene X? | Knockout + RNA-seq/proteomics |
| Can gene X be targeted to sensitize cancer cells? | Knockout in cancer cell lines + drug treatment |
How to Study the negative regulation of apoptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Enrichment of sgRNAs targeting anti-apoptotic genes | Discovery of novel negative regulators |
| Annexin V flow cytometry | Phosphatidylserine externalization | Quantification of apoptosis |
| Caspase activity assay | Caspase-3/7/9 activity | Assessment of apoptosis inhibition |
| Western blot | Protein levels of BCL-2, BAX, SIRT1 | Validation of knockout/overexpression |
| Co-immunoprecipitation | Protein-protein interactions | IAP-caspase interactions |
| Ubiquitinome profiling | Ubiquitinated proteins | Identification of UPS substrates |
| RNA-seq | Transcriptional changes | Pathway analysis after gene editing |
| Immunofluorescence | Subcellular localization | Tagged knock-in validation |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens are powerful for identifying negative regulators of apoptosis. Cells are transduced with a sgRNA library, treated with an apoptosis inducer, and surviving cells are sequenced to identify enriched sgRNAs targeting anti-apoptotic genes. This approach has uncovered novel regulators such as RUBCNL/PACER.
Apoptosis Assays
Apoptosis is measured by flow cytometry using Annexin V/propidium iodide staining, caspase activity assays, and TUNEL staining. These methods quantify the frequency of apoptotic cells and can be used to assess the effect of gene knockouts or overexpression.
Proteomics and Ubiquitinome Analysis
Mass spectrometry-based proteomics can identify proteins that are degraded or modified during negative regulation of apoptosis. Ubiquitinome analysis reveals substrates of E3 ligases involved in apoptosis inhibition. This method is useful for mapping the ubiquitin-proteasome system's role in apoptosis.
Transcriptomics and Epigenomics
RNA-seq and ChIP-seq can reveal transcriptional changes and epigenetic regulation of anti-apoptotic genes. For example, SIRT1 deacetylates histones and transcription factors, altering gene expression. These methods help identify upstream regulators of negative regulation of apoptosis.
How CRISPR Can Be Used to Study GO:0043066 negative regulation of apoptotic process
Knockout
CRISPR knockout of anti-apoptotic genes such as BCL2, XIAP, or SIRT1 can sensitize cells to apoptosis inducers. For example, SIRT1 knockout increases apoptosis in macrophages. Knockout models are essential to establish causality in negative regulation of apoptosis.
Point Mutation
Point mutations can be introduced to study specific residues required for anti-apoptotic function. For instance, mutation of the catalytic cysteine in IAPs abolishes their ubiquitin ligase activity and anti-apoptotic function. CRISPR point mutation knock-in allows precise modeling of disease-associated variants.
Knock-in
Knock-in of tagged versions (e.g., GFP, FLAG) of anti-apoptotic proteins enables live-cell imaging and proteomic analysis. Tagged RUBCNL/PACER knock-in has been used to study its localization and interactions. Knock-in of reporter genes under apoptotic promoters can monitor pathway activity.
Overexpression
CRISPR-mediated overexpression via safe-harbor knock-in (e.g., AAVS1) allows stable, tunable expression of anti-apoptotic genes. Overexpression of BCL-2 or SIRT1 protects cells from apoptosis. This approach is useful for gain-of-function studies and drug screening.
How EDITGENE Supports negative regulation of apoptotic process Research
Researchers studying negative regulation of apoptotic process-related genes often need to determine whether a candidate gene is causally involved in apoptosis inhibition, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of apoptotic process research.
Frequently Asked Questions About negative regulation of apoptotic process
What is negative regulation of apoptotic process?
Negative regulation of apoptotic process (GO:0043066) is any cellular process that stops, prevents, or reduces the frequency, rate or extent of apoptotic cell death.
What genes are involved in negative regulation of apoptotic process?
Key genes include SIRT1, BCL2, BCL2L1, MCL1, XIAP, BIRC2, BIRC3, RUBCNL, and IRF9.
How does SIRT1 negatively regulate apoptosis?
SIRT1 deacetylates p53, FOXO, and BAX, reducing their pro-apoptotic activity and promoting cell survival.
What is the role of IAPs in apoptosis inhibition?
IAPs bind and inhibit caspases, and some IAPs have E3 ubiquitin ligase activity that targets caspases and RIPK1 for degradation.
How is negative regulation of apoptosis studied?
Common methods include CRISPR knockout screens, Annexin V flow cytometry, caspase activity assays, proteomics, and RNA-seq.
What diseases are linked to defective apoptosis inhibition?
Cancer, autoimmune diseases, inflammatory conditions, and ischemia-reperfusion injury are linked to dysregulated apoptosis inhibition.
Can CRISPR be used to study negative regulation of apoptosis?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect anti-apoptotic gene function.
What is the difference between positive and negative regulation of apoptosis?
Positive regulation promotes apoptosis, while negative regulation inhibits it, tipping the balance toward cell survival.
How does the ubiquitin-proteasome system regulate apoptosis?
The UPS degrades pro-apoptotic proteins such as BAX and p53, thereby inhibiting apoptosis.
What is the role of autophagy in negative regulation of apoptosis?
Autophagy proteins like RUBCNL/PACER can repress RIPK1-dependent apoptosis, linking autophagy to cell survival.
Conclusion
Negative regulation of apoptotic process (GO:0043066) is a critical biological process that controls cell survival and is implicated in cancer, inflammation, and aging. Understanding its molecular mechanisms, key genes, and regulatory networks is essential for developing targeted therapies. CRISPR-based models and functional genomics provide powerful tools to dissect these pathways and identify new therapeutic targets.
References
- 1. Rojas-Rivera D et al.. 2024. The autophagy protein RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis.. Autophagy 20(11):2444-2459 PMID: 38873940
- 2. Yang H et al.. 2021. Sirt1 activation negatively regulates overt apoptosis in Mtb-infected macrophage through Bax.. Int Immunopharmacol 91:107283 PMID: 33373810
- 3. Solary E et al.. 2000. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies.. Leukemia 14(10):1833-49 PMID: 11021759
- 4. Kadono K et al.. 2022. Myeloid Ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.. J Hepatol 76(4):896-909 PMID: 34871625
- 5. Feltham R et al.. 2012. IAPS and ubiquitylation.. IUBMB Life 64(5):411-8 PMID: 22362579
- 6. Liu Y et al.. 2021. Negative Regulation of SIRT1 by IRF9 Involved in Hyperlipidemia Acute Pancreatitis Associated with Kidney Injury.. Dig Dis Sci 66(4):1063-1071 PMID: 32462510
- 7. Abbas R et al.. 2021. Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.. Cells 10(12) PMID: 34943974
- 8. Warner HR. 1997. Aging and regulation of apoptosis.. Curr Top Cell Regul 35:107-21 PMID: 9192177
